Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.
A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.
An interim analysis of the IMpower110 study has demonstrated an overall survival improvement with atezolizumab versus chemotherapy in treatment-naïve patients with stage IV non-small-cell lung cancer and high levels of PD-L1 expression.
Individuals with advanced non-small-cell lung cancer derive an overall survival benefit from first-line treatment with nivolumab plus ipilimumab irrespective of PD-L1 expression, report the CheckMate 227 investigators.
Research published in JAMA Oncology shows that patients with EGFR-mutated lung adenocarcinoma have prolonged progression free survival when tyrosine kinase inhibitor treatment is supplemented with metformin.
The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.
The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR-mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.
Immune checkpoint inhibitor-induced inflammatory arthritis among patients with cancer may need long-term management by rheumatologists after cessation of treatment, but does not appear to affect cancer outcomes, say researchers.
Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.
Trilaciclib affords myelopreservation in individuals with small-cell lung cancer treated with first-line chemotherapy, without impacting treatment efficacy, research indicates.
Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.
Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.
The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.
Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.
Combining low-dose computed tomography with a blood microRNA test can help establish the most appropriate screening frequency among heavy smokers at risk for lung cancer, study data show.
Video-assisted thoracic surgery lobectomy is associated with less pain, fewer in-hospital complications, and shorter hospital stays compared with open lobectomy for early-stage lung cancer, data from the VIOLET study indicate.
Three-year results from the KEYNOTE-024 trial point to the durable efficacy of pembrolizumab monotherapy when used for the first-line treatment of metastatic non-small-cell lung cancer.
Exploratory analyses from two KEYNOTE trials reported at the IASLC World Conference on Lung Cancer 2019 in Barcelona, Spain, rule out a significant correlation between tumor mutational burden and survival of patients with non-small-cell lung cancer who are treated with pembrolizumab and chemotherapy.
Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.
The development of immune-related adverse events is associated with improved clinical outcomes in response to immune checkpoint blockade in patients with small-cell lung cancer, suggests a chart review.